Cargando…

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing

ALK-break positive non-small cell lung cancer (NSCLC) patients initially respond to crizotinib, but resistance occurs inevitably. In this study we aimed to identify fusion genes in crizotinib resistant tumor samples. Re-biopsies of three patients were subjected to paired-end RNA sequencing to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saber, Ali, van der Wekken, Anthonie J., Kok, Klaas, Terpstra, M. Martijn, Bosman, Lisette J., Mastik, Mirjam F., Timens, Wim, Schuuring, Ed, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821611/ https://www.ncbi.nlm.nih.gov/pubmed/27045755 http://dx.doi.org/10.1371/journal.pone.0153065

Ejemplares similares

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
por: Wei, Jiacong, et al.
Publicado: (2020)

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer
por: Saber, Ali, et al.
Publicado: (2016)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
por: Li, Weiting, et al.
Publicado: (2022)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
por: van der Wekken, A. J., et al.
Publicado: (2017)

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
por: Wei, Jiacong, et al.
Publicado: (2021)

Immune microenvironment composition in non‐small cell lung cancer and its association with survival
por: Tamminga, Menno, et al.
Publicado: (2020)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
por: Liu, Bin, et al.
Publicado: (2019)

CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2022)

Current Smoking is Associated with Decreased Expression of miR-335-5p in Parenchymal Lung Fibroblasts
por: Ong, Jennie, et al.
Publicado: (2019)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(®) and ISET
por: Tamminga, Menno, et al.
Publicado: (2020)

P031: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
por: Veldman, Johanna, et al.
Publicado: (2022)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
por: Kerner, Gerald S. M. A., et al.
Publicado: (2013)

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
por: Li, Jingjing, et al.
Publicado: (2021)

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
por: Boonstra, Pieter A., et al.
Publicado: (2020)

Differential miRNA Expression Profiles in Cumulus and Mural Granulosa Cells from Human Pre-ovulatory Follicles
por: Andrei, Daniela, et al.
Publicado: (2019)

Microarray amplification bias: loss of 30% differentially expressed genes due to long probe – poly(A)-tail distances
por: Boelens, Mirjam C, et al.
Publicado: (2007)

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform
por: Bisschop, Cornelis, et al.
Publicado: (2018)

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2023)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Cortactin expression predicts poor survival in laryngeal carcinoma
por: Gibcus, J H, et al.
Publicado: (2008)

Marked TGF-β-regulated miRNA expression changes in both COPD and control lung fibroblasts
por: Ong, J., et al.
Publicado: (2019)

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
por: Donker, H. C., et al.
Publicado: (2023)

Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0‐staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm
por: Boeve, Koos, et al.
Publicado: (2021)

Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients
por: Meng, Pei, et al.
Publicado: (2019)

Distinct Biomarker Profiles and Clinical Characteristics in T1‐T2 Glottic and Supraglottic Carcinomas
por: Wachters, Jan E., et al.
Publicado: (2020)

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
por: Meertens, Marinda, et al.
Publicado: (2023)

Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells
por: Teteloshvili, Nato, et al.
Publicado: (2018)

PTEN Is Associated With Worse Local Control in Early Stage Supraglottic Laryngeal Cancer Treated With Radiotherapy
por: Bruine de Bruin, Leonie, et al.
Publicado: (2019)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

High pATM is Associated With Poor Local Control in Supraglottic Cancer Treated With Radiotherapy
por: Bruine de Bruin, Leonie, et al.
Publicado: (2020)

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
por: Koopman, Bart, et al.
Publicado: (2021)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qimq54ej1tpo879qqa0jjima8m